Nippon Shinyaku

4516 · TSE · Japan

Public Market Listing

4516TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Nippon Shinyaku are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
4Approved
2Phase 3 / Filed
0Phase 1–2 / Early
12Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Fenfluramine(Fintepla)
Approved
Serotonin 5-HT2 receptorsSmall molecule
EpilepsyRett SyndromeDevelopmental and Epileptic EncephalopathiesDravet SyndromeLennox-Gastaut Syndrome
Ferric derisomaltose(Monoferric / Monofer)
Approved
Iron repletionOther
Heart FailureChronic Kidney DiseaseIron Deficiency Anemia
Tadalafil(Adcirca)
Approved
PDE5Small molecule
Pulmonary Arterial Hypertension
Approved
DNA synthesis (cytarabine, antimetabolite) / Topoisomerase IISmall molecule
Acute Myeloid Leukemia
Phase 3
Iduronate-2-sulfatase (IDS)Gene therapy / editing
Mucopolysaccharidosis Type II
Phase 3
Cardiac cell therapyCell therapy
Heart FailureDuchenne Muscular Dystrophy

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
Ferric derisomaltose · Monoferric / MonoferPhase 3Iron Deficiency, Anaemia in Children
Est. primary completion 2027-04-30 · NCT05179226 · CT.gov ↗
What to watch
November 2027 (1)
Fenfluramine · FinteplaPhase 3CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Est. primary completion 2027-11-08 · NCT05064878 · CT.gov ↗
What to watch
December 2027 (1)
Ferric derisomaltose · Monoferric / MonoferPhase 3Chronic Heart Failure, Iron Deficiencies
Est. primary completion 2027-12-01 · NCT06929806 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Clemidsogene lanparvovecPhase 3MPS II, Hunter Syndrome (MPS II)
Est. primary completion 2028-04-30 · NCT07236606 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Fenfluramine · FinteplaPhase 3Rett Syndrome
Est. primary completion 2029-02-06 · NCT07503444 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(14)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 November 2026FDA action datederamiocelPDUFA extended to 22 November 2026 for deramiocel
US, FDA · Capricor Therapeutics · Source ↗

Recent

22 August 2026FDA action datederamiocelPDUFA target action date set for deramiocel BLA
US, FDA · Source ↗
10 March 2026Filing acceptedderamiocelFDA lifts CRL and resumes review of deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
8 February 2026FDA action dateClemidsogene lanparvovecFDA extends PDUFA date for RGX-121 BLA to February 8, 2026
US, FDA · Source ↗
7 February 2026Complete response letterRGX-121FDA issues Complete Response Letter for the RGX-121 BLA in MPS II
US, FDA · REGENXBIO Inc. · Source ↗
8 December 2025Topline resultFenfluramineGEMZ phase 3 study in CDKL5 deficiency disorder meets primary endpoint
3 December 2025Topline resultderamiocelHOPE-3 Phase 3 meets primary endpoint
Capricor Therapeutics · Source ↗
9 November 2025FDA action dateClemidsogene lanparvovecPDUFA target action date set for RGX-121
US, FDA · Source ↗
31 August 2025FDA action datederamiocelPDUFA target date set for deramiocel
US, FDA · Source ↗
11 July 2025Complete response letterderamiocelFDA issues a complete response letter for the deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
27 June 2025Topline resultFenfluramineGEMZ Phase 3 (NCT05064878) in CDKL5 deficiency disorder met its primary and key secondary endpoints
UCB · Source ↗
13 May 2025Filing acceptedClemidsogene lanparvovecFDA accepts BLA for RGX-121 in MPS II
US, FDA · Source ↗
13 May 2025Priority reviewClemidsogene lanparvovecFDA grants Priority Review to RGX-121 BLA
US, FDA · Source ↗

The 12 most recent of 13 past events are shown.

Financial reports

No financial reports recorded.